Liver carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The overexpression of 91H promotes tumour growth and metastasis, and is associated with a poor prognosis of HCC at least partially by positively regulating the expression of IGF2 through bivalent histone modification changes characterized by H3K4me3 and H3K27me3 at the P3 and P4 promoters.
|
31724285 |
2020 |
Liver carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The unmethylation rate of IGF-II P3 CpG sites was 100% in the HCC-, 52.5% in the paracancerous-, and none (0%) in the distal noncancerous-tissues.
|
30692043 |
2019 |
Liver carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Human insulin-like growth factor (IGF) axis affects the molecular pathogenesis of hepatocellular carcinoma (HCC), especially in the abnormality of hepatic IGF-I receptor (IGF-IR) or IGF-II expression as a key molecule in hepatocarcinogenesis.
|
30360707 |
2019 |
Liver carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
IGF2 mRNA upregulation was observed in 9.4% of HCC and was not associated with higher INSRA:INSRB ratios.
|
30849481 |
2019 |
Liver carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
We found that sodium ascorbate blocked HCC-induced activation of sulfatase-2 leading to restoration of HSPGs receptors associated with reduction in IGF-2 and glypican-3.
|
29669302 |
2018 |
Liver carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Genome wide expression profiling of CTCs using this approach demonstrates CTC heterogeneity and helps detect known oncogenic drivers in HCC such as IGF2.
|
30068984 |
2018 |
Liver carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The LINC01138 locus is frequently amplified in HCC; the LINC01138 transcript is stabilized by insulin like growth factor-2 mRNA-binding proteins 1/3 (IGF2BP1/IGF2BP3) and is associated with the malignant features and poor outcomes of HCC patients.
|
29679004 |
2018 |
Liver carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
In epidemiologic and clinicopathological studies on chronic liver disease (CLD), lowered serum levels, decreased tissue expression of IGF1, elevated production of IGF1R and variable IGF2 expression has been noted, from the start of preneoplastic alterations up to the developed hepatocellular carcinoma (HCC) stage.
|
29702590 |
2018 |
Liver carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, inhibition of the menin/MLL interaction via MI-2/3 reduced IGF2 expression, inhibited the IGF1R-AKT pathway, and significantly repressed HCC with robust expression of IGF2.
|
29413895 |
2018 |
Liver carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Methylation in MIRLET7A3 Gene Induces the Expression of IGF-II and Its mRNA Binding Proteins IGF2BP-2 and 3 in Hepatocellular Carcinoma.
|
30733684 |
2018 |
Liver carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
These findings implicate the activation of STAT3 as one pathway that may mediate resistance to IGF-II-targeted therapy in HCC.
|
29933129 |
2018 |
Liver carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The effects of IGF-II on cell proliferation, cell cycle, apoptosis, cell migration, and invasion in HCC Huh7 cells were investigated in the study.
|
29970663 |
2018 |
Liver carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
At immunohistochemistry (group C), the HCC with loss of cytoplasmic IGF2 expression showed a down-regulation of miR-483-3p (fold increase 0.57).
|
29707155 |
2018 |
Liver carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Emerging evidence confirms that insulin-like growth factor -II (IGF-II), oncogenes C-myc and N-ras are an essential regulator for development and growth in hepatocellular carcinoma (HCC).
|
27768959 |
2017 |
Liver carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
MiR-483-5p promotes IGF-II transcription and is associated with poor prognosis of hepatocellular carcinoma.
|
29245946 |
2017 |
Liver carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Signaling via the insulin-like growth factor (IGF) pathway is aberrantly activated in HCC by IGF2 overexpression.
|
27614046 |
2016 |
Liver carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The overexpression of transcripts from P3 and P4 promoters of the insulin-like growth factor 2 (IGF2) gene is observed in hepatocellular carcinoma (HCC).
|
24423280 |
2015 |
Liver carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The IGF2 mRNA-binding protein IMP2-2/IGF2BP2-2/p62 was originally identified as an autoantigen in HCC.
|
26426686 |
2015 |
Liver carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
In order to explore the effect of daintain/AIF-1 on the progression of hepatocellular carcinoma (HCC), enzyme-linked immunosorbent assay (ELISA) and reverse transcription polymerase chain reaction (RT-PCR) were performed to examine the secretion and gene expression of (IGF)-1, IGF-2 and IGFBP-3.
|
25998745 |
2015 |
Liver carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Forced expression of miR-96-5p and miR-182-5p in the HCC cell line HuH-7 had inducing effects on IGFBP-3 and IGF-II transcripts.
|
25739014 |
2015 |
Liver carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
miR-1275: A single microRNA that targets the three IGF2-mRNA-binding proteins hindering tumor growth in hepatocellular carcinoma.
|
26160756 |
2015 |
Liver carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
We focused our subsequent analyses on the Insulin-like growth factor 2 messenger RNA (mRNA)-binding protein 1 (IGF2BP1) representing the most strongly up-regulated RBP in HCC in our cohort.
|
24395596 |
2014 |
Liver carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The combination of IGF-2+3580 AA homozygosity and IGF-2R 1619 GG homozygosity presented a significant protective effect against HCC (OR=0.16,95% CI=0.08-0.34, P=0.005).
|
24656929 |
2014 |
Liver carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Sirt6-deficient hepatocytes showed up-regulation of established hepatocellular carcinoma (HCC) biomarkers alpha-fetoprotein (Afp), insulin-like growth factor 2 (Igf2), H19, and glypican-3.
|
23526469 |
2013 |
Liver carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Collectively, these data support the concept for dual IGF-1R/IR targeting in HCC, where EMT status and expressions of IGF-2 and IR may be used to identify those patients who are most likely to benefit from treatment with an IGF-1R/IR dual inhibitor.
|
22161861 |
2012 |